ReviewPrecision chemistry2025
Advances in Epigenomic Sequencing and Their Applications in Cancer Diagnostics.
Review in Precision chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Integrative Epigenomics: Bioinformatics Strategies for Multi-Omics Data Analysis in Health and Disease.Epigenomes · 2026Review
- Advances in spatial omics for the analysis of prostate cancer.Analytical and bioanalytical chemistry · 2026Review
- Nutrient-Sensitive Epigenetic Modifiers as Candidate Biomarkers of Metabolic Dysfunction in Obesity: A Nutrigenomic Review.International journal of molecular sciences · 2026Review
- Epigenetic Biomarkers for Predicting Nucleoside Analog Drug Response and Resistance in Cancer.Biomolecules · 2026Review
- Epigenetic profiling of circulating cell-free DNA for early detection and minimal residual disease assessment in lung cancer: a focus on DNA methylation.Frontiers in oncology · 2026Review
- Editorial: Nutritional epigenetics and cancer prevention: mechanisms and biomarkers.Frontiers in nutrition · 2026Article
- [Identification of SORD as A Key Gene Mediating Osimertinib Primary Resistance in EGFR-Mutant Lung Adenocarcinoma via Machine Learning and Methylomics].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Article
- Precision Chemistry in Precision Diagnostics.Precision chemistry · 2025Article
- Histone-modifying enzymes as drivers and therapeutic targets in androgen-resistant prostate cancer.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cancer, a globally prevalent and life-threatening disease, remains a major area of focus in biomedical research. However, its substantial heterogeneity and complex pathogenesis continue to pose significant challenges for accurate diagnosis and effective treatment. The rapid advancement of epigenomic sequencing technologies has opened avenues by uncovering the epigenetic hallmarks and underlying pathology of cancer. As a result, these technologies have become invaluable tools in advancing cancer diagnostics and connecting research with clinical applications. This review briefly overviews epigenomic modifications and their significance in cancer diagnostics, highlighting potential epigenomic biomarkers with clinical applicability. We also examine emerging techniques in bulk and single-cell sequencing approaches, alongside spatial tools, highlighting their integration with multiomics technologies for cancer diagnostics. Particular attention is given to the analysis of key epigenetic characteristics, such as DNA methylation, histone modifications, and chromatin accessibility. Additionally, we summarize the diagnostic applications of these technologies and evaluate their current adoption in clinical settings. Challenges, limitations, and future directions for advancing epigenomic sequencing toward routine clinical diagnostics are also discussed. This review aims to provide scientists and clinicians with a comprehensive resource, encouraging further exploration and adoption of epigenomic sequencing technologies to drive progress in precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.